Abbasi Hamid, Khoshdooz Sara, Alem Emad, Bakhshimoghaddam Farnush, Doaei Saeid, Goodarzi Mark O
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran.
Faculty of Medicine, Guilan University of Medical Science, Rasht, Iran.
J Nutr. 2024 Dec;154(12):3505-3520. doi: 10.1016/j.tjnut.2024.10.004. Epub 2024 Oct 5.
Multiple sclerosis (MS) is an inflammatory neuroimmune disease with a multifaceted etiology and long-lasting adverse effects. Several studies have explored the role of 25-hydroxyvitamin D (25(OH)D) serum levels, vitamin D receptor (VDR) gene polymorphisms, and vitamin D supplementation (VDS) in individuals with MS.
The aim of this study was to evaluate the relationship of MS with 25(OH)D serum levels, VDR gene polymorphisms, and VDS.
We assessed relevant articles published in PubMed, Scopus, and Web of Science from the inception up to 24 February, 2024. Meta-analyses that investigated the link of 25(OH)D serum levels, VDR gene polymorphisms including Apal (rs7975232), BsmI (rs1544410), Taql (rs731236), and Fokl (rs10735810), and VDS with the risk and clinical manifestations of MS were included. The methodological quality of selected articles was assessed by the Assessment of Multiple Systematic Reviews version 2. The statistical analysis of this umbrella review was carried out using RStudio version 2023.03.1 and R version 4.3.2, simultaneously.
A total of 23 of 304 records were entered into this umbrella review with a pooled sample size of 37,567 participants. Eleven articles were rated as high quality, 1 was moderate quality, 1 was low quality, and 10 were critically low quality. The homozygote model of FokI (FF+ff compared with Ff) was significantly associated with an 8% reduction of MS risk (odds ratio: 0.92, 95% confidence interval: 0.86, 0.98; I = 0%, P > 0.99).
According to existing clinical evidence, the risk of MS may be associated with VDR gene polymorphism. Further studies are needed to explore the association of MS and vitamin D.
This trial was registered at International Prospective Register of Systematic Reviews (PROSPERO) as registration number CRD42024521541.
多发性硬化症（MS）是一种具有多方面病因和长期不良影响的炎症性神经免疫疾病。多项研究探讨了25-羟基维生素D（25(OH)D）血清水平、维生素D受体（VDR）基因多态性以及维生素D补充剂（VDS）在MS患者中的作用。
本研究旨在评估MS与25(OH)D血清水平、VDR基因多态性和VDS之间的关系。
我们评估了从创刊至2024年2月24日在PubMed、Scopus和Web of Science上发表的相关文章。纳入了调查25(OH)D血清水平、VDR基因多态性（包括Apal（rs7975232）、BsmI（rs1544410）、Taql（rs731236）和Fokl（rs10735810））以及VDS与MS风险和临床表现之间联系的荟萃分析。使用《多个系统评价评估》第2版评估所选文章的方法学质量。本伞状综述的统计分析同时使用RStudio 2023.03.1版和R 4.3.2版进行。
304条记录中的23条被纳入本伞状综述，汇总样本量为37567名参与者。11篇文章被评为高质量，1篇为中等质量，1篇为低质量，10篇为极低质量。FokI的纯合子模型（FF + ff与Ff相比）与MS风险降低8%显著相关（优势比：0.92，95%置信区间：0.86，0.98；I² = 0%，P > 0.99）。
根据现有临床证据，MS的风险可能与VDR基因多态性有关。需要进一步研究来探索MS与维生素D之间的关联。
本试验在国际前瞻性系统评价注册库（PROSPERO）注册，注册号为CRD42024521541。
